STOCK TITAN
  1. Home
  2. Sec-filings
  3. MANE
  4. [Form 4] Veradermics, Inc Insider Trading Activity

Suvretta Capital group steps up Veradermics (MANE) insider share buying

Filing Impact
(Very High)
Filing Sentiment
(Very Positive)
Form Type
4

Rhea-AI Filing Summary

Veradermics, Inc. reported multiple insider share purchases by major holders linked to Suvretta Capital Management, LLC over several days in early February 2026. These indirect open‑market transactions involved common stock at prices in the mid‑$30s per share.

On February 4, 2026, reported indirect purchases included 53,344 shares of common stock at $37.11 per share, bringing one reported indirect position to 3,604,141 shares. Additional indirect buys continued on February 5 and 6, 2026, including 19,338 shares at $36.55 per share, after which one indirect holding stood at 520,453 shares.

Positive

  • None.

Negative

  • None.
Insider SUVRETTA CAPITAL MANAGEMENT, LLC, Cowen Aaron, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.
Role Director, 10% Owner | 10% Owner | Director, 10% Owner | Director, 10% Owner
Bought 282,674 shs ($10.54M)
Type Security Shares Price Value
Purchase Common stock, par value $0.00001 per share 11,183 $35.97 $402K
Purchase Common stock, par value $0.00001 per share 19,338 $36.55 $707K
Purchase Common stock, par value $0.00001 per share 3,832 $36.07 $138K
Purchase Common stock, par value $0.00001 per share 19,199 $36.93 $709K
Purchase Common stock, par value $0.00001 per share 38,771 $37.63 $1.46M
Purchase Common stock, par value $0.00001 per share 17,835 $38.67 $690K
Purchase Common stock, par value $0.00001 per share 16,563 $39.80 $659K
Purchase Common stock, par value $0.00001 per share 10,004 $34.25 $343K
Purchase Common stock, par value $0.00001 per share 10,676 $34.74 $371K
Purchase Common stock, par value $0.00001 per share 14,659 $36.27 $532K
Purchase Common stock, par value $0.00001 per share 53,344 $37.11 $1.98M
Purchase Common stock, par value $0.00001 per share 25,908 $38.09 $987K
Purchase Common stock, par value $0.00001 per share 18,489 $38.90 $719K
Purchase Common stock, par value $0.00001 per share 1,720 $34.25 $59K
Purchase Common stock, par value $0.00001 per share 1,835 $34.74 $64K
Purchase Common stock, par value $0.00001 per share 2,519 $36.27 $91K
Purchase Common stock, par value $0.00001 per share 9,168 $37.11 $340K
Purchase Common stock, par value $0.00001 per share 4,453 $38.09 $170K
Purchase Common stock, par value $0.00001 per share 3,178 $38.90 $124K
Holdings After Transaction: Common stock, par value $0.00001 per share — 501,115 shares (Indirect, See footnotes)
Footnotes (1)
  1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1. Notes are included on Exhibit 99.1.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SUVRETTA CAPITAL MANAGEMENT, LLC
(Last) (First) (Middle)
540 MADISON AVENUE
7TH FLOOR
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock, par value $0.00001 per share 02/04/2026 P 10,004(2) A $34.25(2) 3,525,462 I(1) See footnotes(1)(2)
Common stock, par value $0.00001 per share 02/04/2026 P 10,676(3) A $34.74(3) 3,536,138 I(1) See footnotes(1)(3)
Common stock, par value $0.00001 per share 02/04/2026 P 14,659(4) A $36.27(4) 3,550,797 I(1) See footnotes(1)(4)
Common stock, par value $0.00001 per share 02/04/2026 P 53,344(5) A $37.11(5) 3,604,141 I(1) See footnotes(1)(5)
Common stock, par value $0.00001 per share 02/04/2026 P 25,908(6) A $38.09(6) 3,630,049 I(1) See footnotes(1)(6)
Common stock, par value $0.00001 per share 02/04/2026 P 18,489(7) A $38.9(7) 3,648,538 I(1) See footnotes(1)(7)
Common stock, par value $0.00001 per share 02/04/2026 P 1,720(8) A $34.25(8) 372,579 I(1) See footnotes(1)(8)
Common stock, par value $0.00001 per share 02/04/2026 P 1,835(9) A $34.74(9) 374,414 I(1) See footnotes(1)(9)
Common stock, par value $0.00001 per share 02/04/2026 P 2,519(10) A $36.27(10) 376,933 I(1) See footnotes(1)(10)
Common stock, par value $0.00001 per share 02/04/2026 P 9,168(11) A $37.11(11) 386,101 I(1) See footnotes(1)(11)
Common stock, par value $0.00001 per share 02/04/2026 P 4,453(12) A $38.09(12) 390,554 I(1) See footnotes(1)(12)
Common stock, par value $0.00001 per share 02/04/2026 P 3,178(13) A $38.9(13) 393,732 I(1) See footnotes(1)(13)
Common stock, par value $0.00001 per share 02/05/2026 P 3,832(14) A $36.07(14) 397,564 I(1) See footnotes(1)(14)
Common stock, par value $0.00001 per share 02/05/2026 P 19,199(15) A $36.93(15) 416,763 I(1) See footnotes(1)(15)
Common stock, par value $0.00001 per share 02/05/2026 P 38,771(16) A $37.63(16) 455,534 I(1) See footnotes(1)(16)
Common stock, par value $0.00001 per share 02/05/2026 P 17,835(17) A $38.67(17) 473,369 I(1) See footnotes(1)(17)
Common stock, par value $0.00001 per share 02/05/2026 P 16,563(18) A $39.8(18) 489,932 I(1) See footnotes(1)(18)
Common stock, par value $0.00001 per share 02/06/2026 P 11,183(19) A $35.97(19) 501,115 I(1) See footnotes(1)(19)
Common stock, par value $0.00001 per share 02/06/2026 P 19,338(20) A $36.55(20) 520,453 I(1) See footnotes(1)(20)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
SUVRETTA CAPITAL MANAGEMENT, LLC
(Last) (First) (Middle)
540 MADISON AVENUE
7TH FLOOR
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Cowen Aaron
(Last) (First) (Middle)
C/O SUVRETTA CAPITAL MANAGEMENT, LLC
540 MADISON AVENUE, 7TH FLOOR
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Averill Master Fund, Ltd.
(Last) (First) (Middle)
C/O SUVRETTA CAPITAL MANAGEMENT, LLC
540 MADISON AVENUE, 7TH FLOOR
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Averill Madison Master Fund, Ltd.
(Last) (First) (Middle)
C/O SUVRETTA CAPITAL MANAGEMENT, LLC
540 MADISON AVENUE, 7TH FLOOR
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. Notes are included on Exhibit 99.1.
2. Notes are included on Exhibit 99.1.
3. Notes are included on Exhibit 99.1.
4. Notes are included on Exhibit 99.1.
5. Notes are included on Exhibit 99.1.
6. Notes are included on Exhibit 99.1.
7. Notes are included on Exhibit 99.1.
8. Notes are included on Exhibit 99.1.
9. Notes are included on Exhibit 99.1.
10. Notes are included on Exhibit 99.1.
11. Notes are included on Exhibit 99.1.
12. Notes are included on Exhibit 99.1.
13. Notes are included on Exhibit 99.1.
14. Notes are included on Exhibit 99.1.
15. Notes are included on Exhibit 99.1.
16. Notes are included on Exhibit 99.1.
17. Notes are included on Exhibit 99.1.
18. Notes are included on Exhibit 99.1.
19. Notes are included on Exhibit 99.1.
20. Notes are included on Exhibit 99.1.
Remarks:
Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signature
Suvretta Capital Management, LLC; By: /s/ Andrew Nathanson, General Counsel & Chief Compliance Officer 02/09/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions were reported in Veradermics (MANE)?

Major holders associated with Suvretta Capital reported multiple indirect open‑market purchases of Veradermics common stock. The transactions occurred on February 4, 5, and 6, 2026, at various prices in the mid‑$30s per share, increasing reported indirect share holdings.

Who are the reporting persons in the Veradermics (MANE) insider transactions?

The reporting group includes Suvretta Capital Management, LLC, Aaron Cowen, Averill Master Fund, Ltd., and Averill Madison Master Fund, Ltd. They are identified as directors and/or 10% owners, and they reported the transactions jointly with indirect beneficial ownership noted in the filing.

Were the Veradermics (MANE) insider trades direct or indirect holdings?

All reported Veradermics transactions were classified as indirect ownership. Each line in the transaction table shows ownership code “I” with the nature of ownership described as “See footnotes,” indicating the shares are held through related entities rather than directly.

What prices were paid in the Veradermics (MANE) insider share purchases?

The reported open‑market purchases occurred at per‑share prices ranging from about $34 to just under $40. Examples include 53,344 shares at $37.11 per share and 19,338 shares at $36.55 per share during early February 2026.

How many Veradermics (MANE) shares were held after key insider purchases?

Reported indirect holdings increased following these transactions. After buying 53,344 shares at $37.11 on February 4, 2026, one indirect position totaled 3,604,141 shares. After a 19,338‑share purchase at $36.55 on February 6, 2026, another indirect position reached 520,453 shares.

Over what period did the Veradermics (MANE) insider purchases take place?

The insider open‑market purchases took place over three consecutive days. Transactions were reported on February 4, 5, and 6, 2026, with multiple trades recorded on each date, all involving Veradermics common stock at varying prices in that timeframe.